Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11977411 | 1.00 | SMN1; SMN2 (0.53) | SMN1; SMN2CA2ACHEBACE1CA1 | |
| SCHEMBL8550469 | 0.92 | CA2 (0.58) | SMN1; SMN2CA2ACHEBACE1CA1 | |
| SCHEMBL20200244 | 0.90 | SMN1; SMN2 (0.54) | SMN1; SMN2CA2ACHEBACE1CA1 | |
| SCHEMBL77617 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2CA2ACHEBACE1CA1 | |
| SCHEMBL77618 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2CA2ACHEBACE1CA1 | |
| SCHEMBL715116 | 0.86 | SMN1; SMN2 (0.67) | SMN1; SMN2CA2ACHEBACE1CA1 | |
| SCHEMBL3050606 | 0.84 | SMN1; SMN2 (0.65) | SMN1; SMN2CA2ACHEBACE1CA1 | |
| SCHEMBL8543783 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2CA2CA1NPC1RAB9A | |
| SCHEMBL24068020 | 0.81 | KDM4E (0.59) | SMN1; SMN2CA2CA1NPC1RAB9A | |
| SCHEMBL19233522 | 0.81 | NFE2L2 (0.52) | SMN1; SMN2CA2ACHECA1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441700-B2 | Hydrogenation of imines with RU complexes | FIRMENICHI SA (CH) | 2025-10-14 | — | — | US | disclosed |
| EP-3931176-B1 | HYDROGENATION OF IMINES WITH RU COMPLEXES | FIRMENICH & CIE (CH) | 2024-02-14 | — | — | EP | disclosed |
| US-11498901-B2 | Hydrogenation of imines with Ru complexes | FIRMENICH SA (CH) | 2022-11-15 | — | — | US | disclosed |
| US-20220162181-A1 | HYDROGENATION OF IMINES WITH RU COMPLEXES | FIRMENICH SA (CH) | 2022-05-26 | — | — | US | disclosed |
| US-20210371382-A1 | HYDROGENATION OF IMINES WITH RU COMPLEXES | FIRMENICH SA (CH) | 2021-12-02 | — | — | US | disclosed |
| EP-3700892-A1 | HYDROGENATION OF IMINES WITH RU COMPLEXES | Firmenich SA (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-0671385-B1 | Method for handling (2-alkyl) acryloyl isocyanate, method for producing (2-alkyl)acryloyl isocyanate, heterocyclic compound, and method for producing heterocyclic compound | NIPPON PAINT CO LTD (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-5663423-A | Method for handling (2-alkyl) (acryloyl) isocyanate, method for stabilizing (2-alkyl) (acryloyl) isocyanate, method for producing (2-alkyl) (acryloyl) isocyanate, heterocyclic compound, and method for producing heterocyclic compound | NIPPON PAINT CO., LTD (JP) | 1997-09-02 | — | — | US | disclosed |
| US-5532360-A | REACTING WITH AZOMETHINE COMPOUND TO FORM HETEROCYCLIC COMPOUND | NIPPON PAINT CO., LTD. (JP) | 1996-07-02 | — | — | US | disclosed |
| EP-0671385-A1 | Method for handling (2-alkyl) acryloyl isocyanate, method for producing (2-alkyl)acryloyl isocyanate, heterocyclic compound, and method for producing heterocyclic compound | Nippon Paint Co., Ltd. (JP) | 1995-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441700-B2 | Hydrogenation of imines with RU complexes | HRH3, HNMT, HRH4 | SMN1; SMN2 2231/4885CA2 2931/4885ACHE 3844/4885 |
| US-20210371382-A1 | HYDROGENATION OF IMINES WITH RU COMPLEXES | HRH3, HRH4, HRH2 | SMN1; SMN2 4252/4885CA2 2318/4885ACHE 2172/4885 |
| US-11498901-B2 | Hydrogenation of imines with Ru complexes | HRH3, HRH4, HRH2 | SMN1; SMN2 4252/4885CA2 2318/4885ACHE 2172/4885 |
| US-20220162181-A1 | HYDROGENATION OF IMINES WITH RU COMPLEXES | HRH3, HNMT, HRH4 | SMN1; SMN2 2231/4885CA2 2931/4885ACHE 3844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.